Opicapone: A Review in Parkinson's Disease

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder.
• Motor fluctuations, particularly end-of-dose (EoD) effects, significantly impact patient quality of life.
• Levodopa/dopa-decarboxylase inhibitor (L-dopa/DDCI) therapy is standard but often insufficient for long-term motor control.

Purpose of the Study:

• To evaluate the efficacy and tolerability of oral opicapone as adjunctive therapy in adults with PD and EoD motor fluctuations.
• To compare opicapone's efficacy against placebo and entacapone for managing motor fluctuations.

Main Methods:

• Analysis of data from pivotal global trials (BIPARK 1, BIPARK 2), open-label extensions (OLEs), and a real-world study (OPTIPARK).
• Opicapone 50 mg once daily was administered as an add-on to L-dopa/DDCI and other PD therapies.
• Assessment of changes in ON- and OFF-state time, and comparison with placebo and entacapone.

Main Results:

• Opicapone demonstrated significant improvements in ON- and OFF-state time compared to placebo.
• Opicapone achieved noninferiority to entacapone in improving OFF time.
• The beneficial effects on motor fluctuations were sustained for up to one year in OLE studies.
• Opicapone was generally well-tolerated in the studied patient population.

Conclusions:

• Adjunctive opicapone is an effective and well-tolerated treatment for adults with PD and EoD motor fluctuations.
• Opicapone offers a valuable therapeutic option for patients inadequately stabilized on L-dopa/DDCI therapy.
• Opicapone provides sustained benefits in managing motor fluctuations associated with Parkinson's disease.